Yahoo Finance20d
FDA Approves Feasibility Study with SeaStar Medical’s Selective Cytopheretic Device in Adults with Cardiorenal Syndrome
The FDA’s Center for Biologics Evaluation and Research (CBER) granted Breakthrough Device Designation for the SCD in cardiorenal syndrome with LVAD in September 2023. “Oftentimes patients with ...
Nasdaq20d
SeaStar Medical Receives FDA Approval for SCD-ADULT Study Funded by $3.6 Million NIH Grant
FDA approves SeaStar Medical's SCD-ADULT study ... the condition of patients awaiting left ventricular assist device (LVAD) implantation, potentially offering significant advancements in treating ...
Stockhouse20d
FDA Approves Feasibility Study with SeaStar Medical's Selective Cytopheretic Device in Adults with Cardiorenal Syndrome
The FDA’s Center for Biologics Evaluation and Research (CBER) granted Breakthrough Device Designation for the SCD in cardiorenal syndrome with LVAD in September 2023 ... be able to ...